^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CTIM-76

    i
    Other names: CTIM-76, CLDN6xCD3 bsAb
    Company:
    Context Therap, Integral Molecular
    Drug class:
    CD3 agonist, CLDN6 inhibitor
    Related drugs:
    1m
    CNTX-CTIM76-101: A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=80, Recruiting, Context Therapeutics Inc. | Trial primary completion date: Jul 2027 --> Apr 2027
    Trial primary completion date • First-in-human
    |
    CTIM-76
    over1year
    A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=80, Recruiting, Context Therapeutics Inc.
    New P1 trial • Metastases
    |
    CTIM-76